Asarina Pharma receives approval of CTA for phase IIa Tourette study
(Stockholm, 19 May, 2021.) Asarina Pharma’s Clinical Trial Application for a phase IIa study with Sepranolone in Tourette Syndrome has been approved by the Danish Medical Agency, with the study to commence in August 2021 at two sites in Denmark.With Cognitive Behavioral Therapy as first-line treatment for Tourette, and many pharma treatments exhibiting severe side effects, there is a large unmet need for a safe, effective drug therapy in Tourette. In several preclinical studies, Sepranolone has demonstrated a positive tic-reducing effect on par with the antipsychotic drug, Haldol (